Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

614.O1.6 Acute Lymphoblastic Leukemia: Randomized Clinical Trials

Sunday, December 7, 2008: 4:30 PM-6:00 PM
Yerba Buena Ballroom Salon 9 (San Francisco Marriott)
Moderators:
Willye B. Powell, MD and Ching-Hon Pui, MD
4:30 PM
Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD1, Martin Zimmermann, PhD2*, Anja Möricke, MD1*, Georg Mann, MD3*, Maria Grazia Valsecchi, PhD4*, Claus R Bartram, MD5*, Andrea Biondi, MD6*, Renate Panzer-Grümayer, MD3*, André Schrauder, MD1*, Franco Locatelli, MD7*, Alfred Reiter, MD8, Giuseppe Basso, MD9*, Felix Niggli, MD10*, Maurizio Aricò, MD11 and Valentino Conter, MD12*

1Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
2Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
3CCRI, St. Anna Children's Hospital, Vienna, Austria
4Dept of Clinical and Preventive Medicine, Università Milano Bicocca, Monza, Italy
5Institute of Human Genetics, Ruprecht-Karls University, Heidelberg, Germany
6M.Tettamanti Research Center, Pediatric Clinic University of Milan Bicocca, Monza, Italy
7Department of Pediatrics, Fondazione Policlinico San Matteo, University of Pavia, Pavia, Italy
8Dept. of Pediatric Hematology and Oncology, Children's University Hospital, Giessen, Germany
9Pediatrics, University of Padua, Padova, Italy
10Pediatric Hematology/Oncology, University Hospital Zürich, Zürich, Switzerland
11Pediatric Hematology/Oncology, Azienda Ospedaliero-Universitaria Meyer, Florence, Italy
12Department of Pediatrics, University of Milano-Bicocca, Ospedale S. Gerardo, Monza, Italy

4:45 PM
Dexamethasone(DEX)(6mg/sm/d) and Prednisolone(PRED)(60mg/sm/d)in Induction Therapy of Childhood ALL Are Equally Effective : Results of the 2nd Interim Analysis of EORTC Trial 58951

Yves Bertrand, MD1*, Stefan Suciu2, Yves Benoit3*, Alain Robert4*, Brigitte Nelken5*, Anne Uyttebroeck6*, Patrick Lutz7*, Alice Ferster2*, Andre Baruchel, MD8, Lucilia Norton9*, Geneviève Margueritte10*, Pierre-Simon Rohrlich, MD, PhD11*, Martine Munzer12*, Dominique Plantaz13*, Frédéric Millot14*, Patrick Boutard15*, Nicolas Sirvent16*, Claire Hoyoux17*, Liliana Baila18* and Jacques Otten19*

1Pediatric Hematology, CHU Lyon and Université claude Bernard Lyon 1, Lyon, France
2EORTC Leukemia Group, Brussels, Belgium
3Ghent University Hospital, Ghent, Belgium
4CHU Toulouse, Toulouse, France
5Pediatrics Hematology, CHU Lille, Lille
6University Hospital, Leuven, Belgium
7Service Oncologie hématologie pédiatrique, Strasbourg, France
8Dept. of Pediatric Hematology, Hopital Saint Louis, Paris, France
9Hospital escolar San Joao, Porto, Portugal
10CHU Montpellier, Montpellier
11Hematology-Pediatry, INSERM UMR645 - CHU Jean Minjoz, Besançon, France
12CHU Reims, Reims, France
13CHU Grenoble, Grenoble, France
14CHU Poitiers, Poitiers, France
15CHU Caen, Caen, France
16CHU Nice, Nice, France
17Centre Hospitalier Liège, Brussels, Belgium
18EORTC Headquarters, Brussels, Belgium
19University Hospital Brussels, Brussels, Belgium

5:00 PM
Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL):  Children’s Oncology Group Study 1991

Yousif Matloub, MD1, Bruce C. Bostrom, MD2, Stephen P. Hunger, MD3, Anne L Angiolillo, MD4*, Catherine Cole, MD5*, Blythe Thomson, MD6, Meenakshi Devidas, PhD7*, Nyla A. Heerema, PhD8, Mei K La9*, Patrick J. Buckley, MD, PhD10, William L. Carroll, MD11, Naomi Winick, MD12, Harland Sather, PhD13*, James B Nachman, MD14 and Paul S. Gaynon, MD15

1Pediatrics, University of Wisconsin, Madison, WI
2Children's Hospitals & Clinics of Minnesota, Minneapolis, MN
3University of Colorado Denver School of Medicine and The Children's Hospital, Aurora, CO
4hematology/Oncology, Children's National Medical Center, Washington, DC
5Hematology-Oncology, Princess Margaret Hospital for Children, Perth, Australia
6Children's Hosp. & Regional Med. Ctr., Seattle, WA
7Department of Epidemiology & Health Policy Research, University of Florida College of Medicine, Gainesville, FL
8Ohio State University, Columbus, OH
9Operation Center, Children's Oncology Group, Arcadia, CA
10Duke Univ. Medical Ctr., Durham, NC
11New York University Cancer Institute, New York, NY
12University of Texas Southwestern Medical Center, Dallas, TX
13Children's Oncology Group, Arcadia, CA
14Pediatric Hematology/Oncology, Univ. of Chicago Comer Children's Hospital, Chicago, IL
15Out-Patient Towers, Childrens Hosp. of Los Angeles, Los Angeles, CA

5:15 PM
High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Thierry Leblanc, MD1, Judith Landman-Parker, MD2, Marie-Françoise Auclerc, MD1*, Krystell Desseaux1*, Christiane Vermylen, MD3*, Claudine Schmitt, MD4*, Virginie Gandemer, MD5*, Odile Lejars, MD6*, Jean-Pierre Vannier, MD7*, François Demeocq, MD8*, Christian Berthou, MD9*, Gérard Couillault, MD10*, Brigitte Pautard, MD11*, Claire Berger, MD12*, Lionel De Lumley, MD13*, Marianne Debré, MD14*, Gérard Michel, MD15*, Yves Perel, MD16*, Guy Leverger, MD2* and Andre Baruchel, MD1

1Hôpital Saint Louis, Paris, France
2Hôpital Armand Trousseau, Paris
3Catholic University of Louvain, Bruxelles
4Hôpital des Enfants, Nancy
5CHU, Rennes
6Hôpital Clocheville, Tours
7CHU, Rouen
8Hotel Dieu, Clermont-Ferrand
9Hôpital Augustin Morvan, Brest
10CHU, Dijon
11CHU, Amiens
12CHU, Saint-Etienne
13CHU, Limoges
14Hôpital Necker, Paris
15Hôpital d'enfants de la Timone, Marseille
16CHU, Bordeaux

5:30 PM
Improved Outcome with Pulses of Vincristine and Steroids in Continuation Therapy of Children with Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC Randomized Phase III Trial 58951

Barbara De Moerloose1*, Stefan Suciu2, Yves Bertrand3*, Francoise Mazingue4, Alain Robert5*, Anne Uyttebroeck6*, Karima Yacouben7*, Alina Ferster8, Geneviève Margueritte9*, Patrick Lutz10*, Martine Munzer11*, Nicolas Sirvent12*, Lucilia Norton13*, Patrick Boutard14*, Dominique Plantaz15*, Frédéric Millot16*, Pierre Philippet17*, Liliana Baila2*, Yves Benoit1* and Jacques Otten18*

1Ghent University Hospital, Ghent, Belgium
2EORTC Headquarters, Brussels, Belgium
3CHU Lyon, Lyon, France
4CHRU Lille, Lille, France
5CHU Toulouse, Toulouse, France
6University Hospital, Leuven, Belgium
7Hôpital Robert Debre, Paris, France
8Children's Hospital, Brussels, Belgium
9CHU Montpellier, Montpellier, France
10Service Oncologie hématologie pédiatrique, Strasbourg, France
11CHU Reims, Reims, France
12CHU Nice, Nice, France
13Hospital escolar San Joao, Porto, Portugal
14CHU Caen, Caen, France
15CHU Grenoble, Grenoble, France
16CHU Poitiers, Poitiers, France
17Clinique de l'espérance, Montegnée, Belgium
18University Hospital Brussels, Brussels, Belgium

5:45 PM
First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic Leukemia

Yves Chalandon1*, Xavier Thomas1, Sandrine Hayette1*, Jean-Michel Cayuela Sr.2*, Claire Abbal1*, Martine Escoffre-Barbe, MD3*, Sebastien Maury1*, Stephane Lepretre1*, Francis Witz4*, Lofti Benboubker1*, Jean-Valère Malfuson1*, Thibaut Leguay5*, Agnes Buzyn1*, Veronique Lheritier1*, Marie-Christine Bene1*, Marina Lafage1*, Norbert Ifrah1* and Herve Dombret1*

1GRAALL Group, Lyon, France
2Hôpital St-Louis, Paris, France
3Hématologie clinique, Hôpital Pontchaillou, Rennes, France
4Hématologie - Médecine interne, Hôpitaux de Brabois, Nancy, France
5Hematology, CHU de Bordeaux, Bordeaux, France

*signifies non-member of ASH